The efficacy of atorvastatin and rosuvastatin on the alternations ofalpha and beta apolipoproteins; a systematic review and meta-analysis

Introduction: Vascular stenosis is one of the causes of cardiovascular diseases (CVDs). Implementing appropriate therapeutic measures for CVDs requires preventing the progression of stenosis. The purpose of this study was to evaluate the efficacy of atorvastatin and rosuvastatin on the levels of alpha and beta apolipoproteinsusing systematic review and meta-analysis. Materials and Methods: This review was performed based on the PRISMA protocol. The ISI, Cochrane Library, Google Scholar, PubMed, and Scopus databases were independently searched by two researchers. MeSH keywords were used to recruit related articles published between 2005 and 2018. The meta-analysis was conducted in STATA 11.1software. Results: A total of 65 articles were found.Out of these, 9 studies were ultimately included in the meta-analysis. The findings showed that alpha lipoprotein levelincreased 4.24 mg/dl (95% CI: -0.03; -8.45) and 8.71 mg/dl (95% CI: -1.95; -15.48) in patients treated with atorvastatin and rosuvastatin respectively. Also, patients treated with either atorvastatin orrosuvastatin revealed 40.55mg/dl (95% CI: 32.16; 45.93) and 44.78 g/dl (95% CI: 34.16; 55.39) decreases in beta-lipoprotein levels respectively. Conclusion: According to the results, rosuvastatin is more efficient than atorvastatinto reducealphaapolipoproteinand increasebetaapolipoproteinwithin ashortperiod.